Document is current
Any future updates will be listed below
-
Authors
Grimes, Martha M. http://orcid.org/0000-0003-2745-550X
Kenney, S. Ray
Dominguez, Dayna R.
Brayer, Kathryn J.
Guo, Yuna
Wandinger-Ness, Angela
Hudson, Laurie G.
-
Funding
Funding for this research was provided by:
National Cancer Institute (R21 CA170375, R25-CA153825, NCI P30 CA118100, NCI P30 CA118100)
National Center for Advancing Translational Sciences (R21 TR001731-01)
U.S. Department of Defense (OC110514 W81XWH-11-OCRP-TEA)
National Institute of General Medical Sciences (P50 GM085273)
National Center for Research Resources (5P20RR016480)
- License Information
-
More Information
Article History
Received: 7 February 2020
Accepted: 8 December 2020
First Online: 7 January 2021
Ethics approval and consent to participate
: <i>Foxn1</i><sup><i>nu</i></sup> NU /J athymic nude mice (6–9 weeks) were purchased from The Jackson Laboratory (Bar Harbor, ME, stock number 002019). For toxicity assessment studies at increased R-ketorolac dose, athymic nude mice were purchased from Charles River Laboratory (Wilmington, MA, strain code 490). Animals were housed according to treatment groups. Water and standard mouse chow were available ad libitum. These studies were performed under an approved Institutional Animal Care and Use Committee (IACUC) protocol (#18–200772-HSC).
: Not applicable.
: AWN and LGH are inventors on US patent 9,125,899 for therapeutic uses of NSAID R-enantiomers. All other authors declare that they have no competing interests.
